secwatch.observer — SEC 8-K summary
======================================

Issuer:     FEMASYS INC (FEMY)
CIK:        0001339005
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001140361-22-040811
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Femasys Q3 net loss widens to $2.98M; FemBloc trial enrollment complete, FemaSeed trial updated
--------------------------------------------------------------------------------

- Q3 net loss $2.98M ($0.25/share) vs $2.26M ($0.19) YoY; revenue $347K (+28.9% on FemVue).
- FemBloc Stage 2 enrollment complete; IDE for pivotal trial on track for Q1 2023.
- FemaSeed trial updated to focus on male factor infertility; expects enrollment completion in 2023.
- FemCerv commercially launched; FemCath expected by year-end.
- Cash $16.0M at Sept 30, down from $24.8M at Dec 31, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339005/000114036122040811/0001140361-22-040811-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339005/000114036122040811/brhc10043970_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-040811

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer